| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 103.05B | 100.97B | 101.36B | 97.40B | 81.60B | 63.57B |
| Gross Profit | 14.70B | 14.37B | 14.11B | 13.81B | 12.15B | 9.77B |
| EBITDA | 4.42B | 5.20B | 4.80B | 4.98B | 3.69B | 2.54B |
| Net Income | 2.42B | 2.66B | 2.50B | 2.74B | 2.09B | 1.34B |
Balance Sheet | ||||||
| Total Assets | 60.61B | 63.69B | 65.13B | 64.08B | 59.15B | 49.32B |
| Cash, Cash Equivalents and Short-Term Investments | 9.46B | 8.97B | 8.23B | 6.49B | 6.05B | 8.79B |
| Total Debt | 1.33B | 1.50B | 1.73B | 5.09B | 2.87B | 1.70B |
| Total Liabilities | 19.78B | 22.84B | 26.05B | 28.47B | 25.98B | 19.39B |
| Stockholders Equity | 40.81B | 40.82B | 39.06B | 35.59B | 33.16B | 29.93B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.72B | 5.97B | -916.00M | -1.25B | 2.77B |
| Operating Cash Flow | 0.00 | 1.82B | 6.08B | -716.00M | -890.00M | 3.14B |
| Investing Cash Flow | 0.00 | -95.00M | -84.00M | -191.00M | -3.81B | -981.00M |
| Financing Cash Flow | 0.00 | -1.31B | -4.42B | 1.20B | 2.05B | -660.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ¥58.68B | 18.87 | ― | 1.85% | 3.60% | -17.45% | |
72 Outperform | ¥49.97B | 13.12 | ― | 1.72% | 36.31% | 101.77% | |
72 Outperform | ¥27.83B | 7.15 | ― | 3.41% | -1.98% | 23.24% | |
66 Neutral | ¥36.43B | 13.12 | ― | 3.02% | 7.09% | 13.13% | |
66 Neutral | ¥27.19B | 9.58 | ― | 4.88% | 3.32% | 31.11% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
Takebishi Corporation reported a significant improvement in its financial performance for the six months ending September 30, 2025, with net sales increasing by 9.7% and operating profit rising by 38.6% compared to the same period in the previous year. This growth reflects the company’s strategic initiatives and robust market positioning, which have positively impacted its operations and stakeholder confidence.
The most recent analyst rating on (JP:7510) stock is a Hold with a Yen2101.00 price target. To see the full list of analyst forecasts on Takebishi Corporation stock, see the JP:7510 Stock Forecast page.
Takebishi Corporation has revised its earnings forecasts for the second quarter and full fiscal year ending March 2026, citing strong sales in its medical business and semiconductors and devices segment. The company anticipates exceeding previous profit forecasts due to efficient management of SG&A expenses, despite economic uncertainties and prolonged inventory adjustments.
The most recent analyst rating on (JP:7510) stock is a Hold with a Yen2101.00 price target. To see the full list of analyst forecasts on Takebishi Corporation stock, see the JP:7510 Stock Forecast page.